非小细胞肺癌中的长非编码RNA:对EGFR-TKI耐药性的影响
Detian Liu1, Xiaolin Lu2, Wentao Huang1
1Department of Thoracic Surgery, Xiangya Hospital of Central South University, Changsha, Hunan, China.
Frontiers in genetics
|July 17, 2023
概括
长非编码RNAs (lncRNAs) 是非小细胞肺癌 (NSCLC) 中的关键参与者,它们对表皮生长因子受体 (EGFR) - 铁氨酸激酶抑制剂 (TKIs) 产生耐药性. 了解lncRNA机制对于克服NSCLC患者的耐药性至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 非小细胞肺癌 (NSCLC) 是全球癌症死亡的主要原因.
- 表皮生长因子受体 (EGFR) - 铁氨酸激酶抑制剂 (TKI) 已改善了EGFR突变NSCLC的结局.
- 对EGFR-TKI获得的耐药性仍然是一个重大的临床挑战,导致疾病进展.
研究的目的:
- 审查长非编码RNAs (lncRNAs) 在NSCLC中介导EGFR-TKI耐药性的关键作用.
- 阐明 lncRNAs 导致治疗耐药性的多种分子机制.
- 讨论lncRNA研究在克服NSCLC耐药性的临床影响和未来方向.
主要方法:
- 对研究 lncRNAs 和EGFR-TKI在NSCLC中的耐药性的综合文献综述.
- 对已识别的 lncRNAs 的功能和作用机制进行分析.
- 综合有关信号通路,细胞过程和涉及的表观遗传修饰的信息.
主要成果:
- lncRNAs通过各种机制调节EGFR-TKI耐药性,包括对绕道信号通路的激活.
- 表型转化,瘤微环境中的细胞间通信和ceRNA网络受到lncRNAs的影响.
- 由lncRNAs介导的表观遗传修饰也对抗性发展有显著的贡献.
结论:
- lncRNAs是NSCLC中EGFR-TKI耐药性的关键调节者,提供潜在的治疗点.
- 了解lncRNA驱动的耐药机制对于开发新型治疗策略至关重要.
- 对lncRNAs的进一步研究有望改善NSCLC患者的临床结果.
关键词:
药物耐药性 耐药性 药物耐药性皮肤上生长因子受体 (EGFR)长非编码RNAs (lncRNA) 是一种长非编码RNA.非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.氨酸激酶抑制剂 (TKI) 的使用更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
相关概念视频
lncRNA - Long Non-coding RNAs
8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Non-LTR Retrotransposons
11.6K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.6K
